Page 3 - Eva Kalias News Today

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, January 10, 2023 - Santhera Pharmaceuticals (SIX: SANN) announces that through a share exchange it will receive the equivalent of CHF

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, January 9, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the

Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting

Pratteln, Switzerland, November 29, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders have approved all proposals by the Board of Directors at the Extraordinary General Meeting

29.11.2022 - Pratteln, Switzerland, November 29, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders have approved all proposals by the Board of Directors at the Extraordinary General Meeting (EGM) held today at the Company’s domicile in ...

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, November 4, 2022 - Santhera Pharmaceuticals (SIX: SANN) provides an update on its activities and is calling an Extraordinary General Meeting (EGM)

Investegate announcements from Santhera Pharmaceuticals Holdi, European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

Pratteln, Switzerland, October 31, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for vamorolone

Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera Announces Half-Year 2022 Financial Results and Provides Corporate Update

Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy